PES: The Effect of Pharyngeal Electrical Stimulation on Peripheral Biomechanical Aspects of Deglutition

Sponsor
Universitaire Ziekenhuizen KU Leuven (Other)
Overall Status
Recruiting
CT.gov ID
NCT05666141
Collaborator
Phagenesis Ltd. (Industry)
80
1
5
26.8
3

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to clarify which biomechanical aspects of swallowing are altered by Pharyngeal Electrical Stimulation (PES) in stroke patients and healthy volunteers.

The peripheral effect of PES intervention on the biomechanics of swallowing will be evaluated with High Resolution Manometry Impedance (HRMI).

Condition or Disease Intervention/Treatment Phase
  • Device: Pharyngeal Electrical Stimulation (Phagenyx)
  • Other: Sham treatment
N/A

Detailed Description

HRMI combines the evaluation of bolus flow patterns (impedance) and pressure (manometry) generated during swallowing.

20 healthy volunteers will participate, of which 10 will receive PES stimulation and 10 will receive Sham treatment.

60 patients with dysphagia after acute first stroke will be included. 20 will receive PES stimulation twice, 20 will receive PES stimulation and afterwards Sham and 20 will receive Sham twice.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
The Effect of Pharyngeal Electrical Stimulation (PES) on Peripheral Biomechanical Aspects of Deglutition
Actual Study Start Date :
Jun 7, 2022
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: PES stimulation in volunteers

10 volunteers will receive PES stimulation. For healthy volunteers, the study protocol includes 1 stimulation trial. Each stimulation trial consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).

Device: Pharyngeal Electrical Stimulation (Phagenyx)
A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters.
Other Names:
  • Phagenyx
  • Sham Comparator: Sham treatment in volunteers

    10 volunteers will receive Sham treatment. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.

    Other: Sham treatment
    In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
    Other Names:
  • Sham
  • Experimental: PES stimulation + PES stimulation in patients

    20 patients will receive PES stimulation twice. For patients, the protocol thus includes 2 stimulation trails. Each stimulation trial consists of 3 PES sessions, so they receive 6 PES sessions in total. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).

    Device: Pharyngeal Electrical Stimulation (Phagenyx)
    A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters.
    Other Names:
  • Phagenyx
  • Other: PES stimulation + Sham treatment in patients

    20 patients will receive PES stimulation and afterwards Sham treatment. During the first stimulation trial, they will receive 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003). During the second stimulation trial, the same method and same device will be used. However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.

    Device: Pharyngeal Electrical Stimulation (Phagenyx)
    A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters.
    Other Names:
  • Phagenyx
  • Other: Sham treatment
    In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
    Other Names:
  • Sham
  • Sham Comparator: Sham treatment + Sham treatment in patients

    20 patients will receive Sham twice. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.

    Other: Sham treatment
    In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
    Other Names:
  • Sham
  • Outcome Measures

    Primary Outcome Measures

    1. Pressure-flow metrics [Change from Baseline at 1-2 hours, 24-72 hours and one week (only in patients) after PES/Sham intervention.]

      The primary outcome measure are alterations of the biomechanics of swallowing, assessed with HRMI. Analysis of these measurements results in pressure impedance metrics of deglutition, called Pressure Flow Analysis (PFA) parameters. These outcomes are numerical measures that can be compared to reference ranges to detect abnormality and to predict aspiration risk through derivation of a swallow risk index (SRI).

    Secondary Outcome Measures

    1. Functional Oral Intake Scale [Change from Baseline at 24-72 hours and one week after last PES/Sham intervention]

      The Functional Oral Intake Scale (FOIS) encompasses the amount and type of food that can be safely consumed, any special preparations of that food, any maneuvers or compensation being used to facilitate the swallow and the amount of supervision required if any. This valid, reliable, concise scale consists of seven levels that range from a patient who is unable to orally consume any food or liquid at Level 1, to a patient who is consuming an oral diet with no restrictions at Level 7.

    2. Brief Esophageal Dysphagia Questionnaire (BEDQ) [Change from Baseline at 24-72 hours and one week after last PES/Sham intervention]

      The Brief Esophageal Dysphagia Questionnaire (BEDQ) is a 10-item self-report measure of oesophageal dysphagia symptom frequency (five items), severity (three items), and impaction (two items) with a total score ranging from 0 (asymptomatic) to 40. Higher scores indicate greater severity and frequency of oesophageal dysphagia symptoms.

    3. Dysphagia Severity Rating Scale (DSRS) in patients [Change from Baseline at 24-72 hours and one week after last PES/Sham intervention]

      The Dysphagia Severity Rating Scale (DSRS) reflects the feeding status of patients across 3 domains: fluid modification, dietary adaptation and supervision requirements. The total score ranges from 0 (normal fluids, normal diet, and eating independently) to 12 (no oral fluids, no oral feeding).

    4. National Institutes of Health Stroke Scale (NIHSS) in patients [Change from Baseline at 24-72 hours and one week after last PES/Sham intervention]

      The National Institutes of Health Stroke Scale (NIHSS) is a reliable, valid 15-item impairment scale for measuring stroke severity. Item scores are summed to a total score ranging from 0 to 42 (the higher the score, the more severe the stroke: <5 limited stroke; 5-14 moderately severe stroke; 15-25 severe stroke; >25 very severe stroke).

    5. Penetration-Aspiration Scale (PAS) in patients [Change from Baseline at 24-72 hours and one week after last PES/Sham intervention]

      The Penetration-Aspiration Scale (PAS) is an 8-point ordinal scale to describe penetration and aspiration events, primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled. Score 1 means that material does not enter the airway (no dysphagia). Score 8 means: material enters the airway, passes below the vocal folds and no effort is made to eject (severe dysphagia). These PAS scores are measured instrumentally by Fibreoptic Endoscopic Evaluation of Swallowing (FEES)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria volunteers:
    Healthy volunteers can participate in this study if they:
    • Are aged between 18 and 80 years old

    • Have no (history of) chronic disease/medication altering the gastrointestinal (GI) motility

    • Have no (history of) gastric or gastrointestinal surgery (except appendectomy and cholecystectomy)

    • Have no (history of) gastrointestinal disease or chronic GI symptoms (heartburn, indigestion/dyspepsia, bloating and constipation)

    • Have FOIS score 7 or BEDQ score <10 at baseline

    • Provide witnessed written informed consent prior to any study procedure And if they do not meet any of the exclusion criteria listed below.

    Exclusion Criteria volunteers:
    Healthy volunteers will be excluded if they:
    • Are aged <18 years or >80 years

    • Have (any history of) a chronic disease/medication altering the GI motility

    • Have (any history of) gastric or gastrointestinal surgery (except appendectomy and cholecystectomy)

    • Have (any history of) gastrointestinal disease or chronic GI symptoms (heartburn, indigestion/dyspepsia, bloating and constipation)

    • Have a FOIS score <7 or a BEDQ score ≥ 10 at baseline

    • Fail to provide witnessed written informed consent prior to any study procedure

    Inclusion Criteria patients:
    Dysphagic stroke patients are eligible for study participation if they:
    • Are admitted to the hospital because of first ever acute stroke (acute means assessment within one month post stroke onset)

    • Hemorrhagic and ischemic stroke

    • Supratentorial and infratentorial stroke

    • Are aged between 18 and 80 years old

    • Are medically stable, alert or arousable

    • Have clinical (oropharyngeal) dysphagia well identified using the FOIS/DSRS/ BEDQ/PAS at baseline. In line with earlier studies, we use the following criteria: a DSRS score of 6 or higher; or a FOIS-score equal to or lower than 5; or a BEDQ score of 10 or higher or (when no oral food intake is possible and DSRS score is 12/FOIS score is 1) a PAS-score of 4 or higher

    • Give (or have a witness to give) voluntary written informed consent And if they do not meet any of the exclusion criteria listed below.

    Exclusion Criteria patients:
    Patients will be excluded from study participation if:
    • They are aged <18 years or >80 years

    • They have an additional condition (e.g. advanced dementia) or diagnosis of a progressive neurological disorder or neuromuscular disorder that may explain dysphagia

    • They have normal swallowing at baseline assessed with FOIS/DSRS/BEDQ/PAS

    • They participate in any other study potentially influencing the outcome of PES, both medicinal or medical device product related and for which the patient signed a consent form for his/her study participation

    • They receive or have received within one month prior to the intended PES treatment any form of non-invasive brain stimulation or percutaneous electrical stimulation therapy to treat dysphagia. (This is no issue, since this type of treatment is not performed at University Hospitals Leuven (UZ Leuven).

    • It is not possible to pass a standard nasogastric tube, for example, nasal, oral or pharyngeal anatomical abnormalities that preclude passage of a feeding tube, oral intubation, history of oesophageal perforation, stricture or pouch

    • They have a cardiac or respiratory condition that might render the insertion of a catheter into the throat unsafe (Atrial fibrillation does not render the insertion of a catheter unsafe)

    • They have a permanently implanted electrical device

    • They are pregnant

    • They present with an oropharyngeal infection. This should be treated and resolved before the PES catheter is inserted

    • They require a magnetic resonance imaging (MRI) scan during PES treatment. Insertion of the PES catheter should either be delayed until such time as the MRI has been completed, or the PES catheter should be removed and discarded and a new catheter inserted after the MRI is completed

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UZ Leuven Leuven Vlaam-Brabant Belgium 3000

    Sponsors and Collaborators

    • Universitaire Ziekenhuizen KU Leuven
    • Phagenesis Ltd.

    Investigators

    • Principal Investigator: Nathalie Rommel, Universitaire Ziekenhuizen KU Leuven

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Universitaire Ziekenhuizen KU Leuven
    ClinicalTrials.gov Identifier:
    NCT05666141
    Other Study ID Numbers:
    • S65439
    First Posted:
    Dec 27, 2022
    Last Update Posted:
    Dec 27, 2022
    Last Verified:
    Nov 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 27, 2022